Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Pulmonology · Stage 4 Pulmonary Sarcoidosis

What is Stage 4 Pulmonary Sarcoidosis? Symptoms & Care

At a Glance

Stage 4 pulmonary sarcoidosis (Scadding Stage IV) indicates that chronic inflammation has caused permanent lung scarring, known as pulmonary fibrosis. Care focuses on preserving remaining lung function, using supplemental oxygen, and managing symptoms rather than suppressing the immune system.

Hearing a diagnosis of Stage 4 pulmonary sarcoidosis (also known as Scadding Stage IV) can feel incredibly overwhelming, especially when medical terminology like “irreversible structural damage” is used. At its core, Stage 4 means that the immune system’s activity in the lungs has led to permanent lung scarring, medically known as pulmonary fibrosis [1][2]. While earlier stages of sarcoidosis involve active inflammation that can often be reversed, Stage 4 indicates that the focus of your care must shift. For patients progressing to this stage, care teams move away from primarily suppressing the immune system and focus instead on preserving remaining lung function, improving daily quality of life, and managing the scarring itself [3][4].

Inflammation vs. Fibrosis: What is the Difference?

To understand Stage 4 sarcoidosis, it helps to distinguish between active inflammation and permanent scarring (fibrosis).

  • Active Inflammation: In earlier stages of sarcoidosis, the immune system creates clumps of inflammatory cells called granulomas [5]. This inflammation is “active” and can often be treated effectively with steroids or other immunosuppressive medications that calm the immune system [3][6]. Your doctor might use a specialized scan called a PET scan to check for active inflammation [7].
  • Fibrosis (Scarring): Over time, chronic inflammation can cause the lung tissue to become thick, stiff, and scarred [5]. This scarring is permanent and cannot be reversed with anti-inflammatory drugs [3]. On a high-resolution CT (HRCT) scan, doctors might see patterns like honeycombing, which are small cystic spaces in the lungs caused by severe scarring [1][2].

Because fibrosis is irreversible, continuing heavy doses of anti-inflammatory medications (like steroids) when there is no active inflammation left can sometimes cause more harm than good due to significant side effects [3][8]. Your doctor will carefully evaluate you to see if you still have active inflammation alongside the scarring, as this will heavily influence your treatment plan [3].

Managing Stage 4 Pulmonary Sarcoidosis

A diagnosis of Stage 4 sarcoidosis means your condition requires a specialized, comprehensive approach [9]. While the scarring cannot be removed, several strategies are used to protect your lungs and help you manage daily symptoms.

Antifibrotic Medications

For patients whose scarring continues to worsen (progressive pulmonary fibrosis), doctors may prescribe antifibrotic medications [10][11]. Unlike steroids which suppress the immune system, antifibrotics work by targeting the pathways that cause scar tissue to build up [11]. While nintedanib is formally recognized for treating progressive fibrotic lung diseases, others like pirfenidone may be used off-label depending on your region and insurance [10][11]. These medications cannot cure existing scarring, but they have been shown to slow down the decline of lung function [10].

Supplemental Oxygen Therapy

As scarring progresses, your lungs may struggle to transfer enough oxygen into your bloodstream, leading to hypoxemia (low blood oxygen) [4]. Your doctor may prescribe supplemental oxygen therapy to be used continuously, only during exercise, or while sleeping [9]. Using supplemental oxygen is a crucial tool that not only relieves the physical sensation of breathlessness but also protects your heart from the strain of pumping oxygen-poor blood [9].

Symptom Management and Palliative Care

Living with Stage 4 sarcoidosis often means dealing with severe chronic cough, fatigue, and daily shortness of breath [4]. Your doctor may integrate palliative care into your treatment [9]. Palliative care is not hospice or end-of-life care—it is a specialized medical approach focused entirely on providing relief from the symptoms and stress of a serious illness, ensuring you can live as comfortably as possible [9].

Pulmonary Rehabilitation

Staying active is vital. Structured exercise training programs, known as pulmonary rehabilitation, are highly recommended for people with advanced sarcoidosis [12]. These programs combine education, breathing techniques, and monitored exercise to improve muscle strength, reduce shortness of breath (dyspnea), and significantly boost your overall quality of life [13][14].

Monitoring for Complications

With Stage 4 sarcoidosis, the structural changes in the lungs can increase the risk of other health issues. Your care team will monitor you closely for complications such as:

  • Pulmonary Hypertension: High blood pressure in the blood vessels of the lungs, which can cause severe shortness of breath and put extra strain on the heart [15][16].
  • Secondary Infections: The scarred areas and cystic spaces in the lungs can become a breeding ground for infections, including fungal infections like chronic pulmonary aspergillosis [17][15].

Lung Transplant Evaluation

If your sarcoidosis causes severe, life-limiting symptoms and declining lung function despite trying all other therapies, a lung transplant may be considered as a last-resort option [18]. Rather than an ominous finality, a transplant represents an opportunity for renewed life and significantly improved daily function [19][20].

Your pulmonologist may refer you for a transplant evaluation early on. It is important to know that being evaluated does not mean you need a transplant immediately. Early referral simply gives your medical team time to thoroughly assess your overall health and ensures you are on the transplant list long before you become too sick to be a good candidate [18]. Survival outcomes for sarcoidosis patients who receive a transplant are comparable to those receiving transplants for other lung diseases [18][20].

Common questions in this guide

What is the difference between active inflammation and fibrosis in sarcoidosis?
Active inflammation involves clumps of immune cells that can often be treated effectively with steroids. Fibrosis is permanent lung scarring that cannot be reversed with anti-inflammatory drugs, requiring a different treatment approach.
Can Stage 4 pulmonary sarcoidosis be cured?
The lung scarring (fibrosis) present in Stage 4 sarcoidosis is permanent and cannot be cured. However, treatments like antifibrotic medications, oxygen therapy, and pulmonary rehabilitation are used to manage symptoms, slow further scarring, and improve quality of life.
Will I still need to take steroids for Stage 4 sarcoidosis?
Steroids are used to treat active inflammation. If your Stage 4 sarcoidosis involves irreversible scarring without any remaining active inflammation, continuing heavy doses of steroids may not be helpful and can cause unnecessary side effects.
What do antifibrotic medications do for sarcoidosis?
Antifibrotic medications, such as nintedanib or pirfenidone, target the pathways that cause scar tissue to build up. While they cannot cure existing scarring, they can help slow down the decline of lung function in patients with progressive fibrosis.
When should a lung transplant be considered for sarcoidosis?
A lung transplant may be considered as a last-resort option if you have severe, life-limiting symptoms and declining lung function despite trying other therapies. Doctors often recommend an early evaluation to ensure you are on the transplant list long before you become too sick.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I need a 6-minute walk test to evaluate whether my oxygen levels drop during activity?
  2. 2.Do my recent HRCT or PET scans show any remaining active inflammation, or am I dealing purely with irreversible fibrosis?
  3. 3.Given my current lung function, am I a candidate for antifibrotic medications like nintedanib?
  4. 4.What specific strategies or medications can we use to aggressively manage my chronic cough and daily shortness of breath?
  5. 5.Is it time for us to discuss an early referral for a lung transplant evaluation, even if I am not ready for one right now?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    High-Resolution CT Scan Fibrotic Patterns in Stage IV Pulmonary Sarcoidosis: Impact on Pulmonary Function and Survival.

    Obi ON, Alqalyoobi S, Maddipati V, et al.

    Chest 2024; (165(4)):892-907 doi:10.1016/j.chest.2023.10.021.

    PMID: 37879560
  2. 2

    An expert overview of pulmonary fibrosis in sarcoidosis.

    Gupta R, Kim JS, Baughman RP

    Expert review of respiratory medicine 2023; (17(2)):119-130 doi:10.1080/17476348.2023.2183193.

    PMID: 36861987
  3. 3

    Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis.

    Gerke AK

    Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030738.

    PMID: 38337432
  4. 4

    New advances in the management of pulmonary sarcoidosis.

    Culver DA, Judson MA

    BMJ (Clinical research ed.) 2019; (367()):l5553 doi:10.1136/bmj.l5553.

    PMID: 31641045
  5. 5

    Fibrotic Pulmonary Sarcoidosis-From Pathogenesis to Management.

    Łyżwa E, Wakuliński J, Szturmowicz M, et al.

    Journal of clinical medicine 2025; (14(7)) doi:10.3390/jcm14072381.

    PMID: 40217830
  6. 6

    The Risk of Sarcoidosis Misdiagnosis and the Harmful Effect of Corticosteroids When the Disease Picture Is Incomplete.

    Arcana RI, Crișan-Dabija R, Cernomaz AT, et al.

    Biomedicines 2023; (11(1)) doi:10.3390/biomedicines11010175.

    PMID: 36672683
  7. 7

    Sarcoidosis detected after COVID‑19 with T‑SPOT.TB positive: A case report.

    Wang Q, Geng J, Liu X, et al.

    Experimental and therapeutic medicine 2024; (27(2)):67 doi:10.3892/etm.2023.12355.

    PMID: 38234612
  8. 8

    The indications for the treatment of sarcoidosis: Wells Law.

    Baughman RP, Judson MA, Wells A

    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2017; (34(4)):280-282 doi:10.36141/svdld.v34i4.6957.

    PMID: 32476859
  9. 9

    An Inventory of Clinical Sarcoidosis Status in the United States.

    Hena KM, Barkes B, Heinrich F, et al.

    Chest 2026; (169(1)):159-173 doi:10.1016/j.chest.2025.07.4091.

    PMID: 40885536
  10. 10

    Pulmonary fibrosis in sarcoidosis.

    Asif H, Ribeiro Neto M, Culver D

    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2023; (40(3)):e2023027 doi:10.36141/svdld.v40i3.14830.

    PMID: 37712364
  11. 11

    The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis.

    Mata Salvador MC, Francesqui J, Sellarés J

    Expert opinion on pharmacotherapy 2024; (25(10)):1317-1324 doi:10.1080/14656566.2024.2377714.

    PMID: 38975682
  12. 12

    Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A RANDOMIZED CONTROLLED TRIAL.

    Naz I, Ozalevli S, Ozkan S, Sahin H

    Journal of cardiopulmonary rehabilitation and prevention 2018; (38(2)):124-130 doi:10.1097/HCR.0000000000000307.

    PMID: 29401114
  13. 13

    Pulmonary Rehabilitation in Patients with Pulmonary Sarcoidosis: Impact on Exercise Capacity and Fatigue.

    Grongstad A, Spruit MA, Oldervoll LM, et al.

    Respiration; international review of thoracic diseases 2020; (99(4)):289-297 doi:10.1159/000506295.

    PMID: 32131065
  14. 14

    The acute impact of resistance training on fatigue in patients with pulmonary sarcoidosis.

    Grongstad A, Vøllestad NK, Oldervoll LM, et al.

    Chronic respiratory disease 2020; (17()):1479973120967024 doi:10.1177/1479973120967024.

    PMID: 33820449
  15. 15

    Advanced Pulmonary Sarcoidosis: Treatment and Monitoring.

    Castelli G, Raja J, Banisadr S, Kouranos V

    Diagnostics (Basel, Switzerland) 2025; (15(23)) doi:10.3390/diagnostics15233061.

    PMID: 41374442
  16. 16

    National Temporal Trends in Hospitalization and Inpatient Mortality in Patients With Pulmonary Sarcoidosis in the United States Between 2007 and 2018.

    Alqalyoobi S, Liao SY, Qureshi W, Obi ON

    Chest 2022; (161(1)):152-168 doi:10.1016/j.chest.2021.07.2166.

    PMID: 34364869
  17. 17

    Pleuroparenchymal Fibroelastosis Lesion in Explanted Lungs of a Patient with Fibrotic Pulmonary Sarcoidosis.

    Kono M, Saito T, Sugiura T, et al.

    Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.6496-25.

    PMID: 41621868
  18. 18

    Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA.

    Taimeh Z, Hertz MI, Shumway S, Pritzker M

    Thorax 2016; (71(4)):378-9 doi:10.1136/thoraxjnl-2015-207497.

    PMID: 26781176
  19. 19

    Use of veno-pulmoarterial ECMO to manage differential oxygenation in a lung transplant candidate.

    Fujimoto R, Usman A, Olia S, et al.

    Perfusion 2025; 2676591251394852 doi:10.1177/02676591251394852.

    PMID: 41184722
  20. 20

    Outcomes of lung transplantation for end stage lung disease with connective tissue disease: a systematic review and meta-analysis.

    Liu J, Zhou R, Li Z, et al.

    BMC pulmonary medicine 2025; (25(1)):264 doi:10.1186/s12890-025-03640-x.

    PMID: 40426174

This page provides educational information about Stage 4 pulmonary sarcoidosis and its management. It does not replace professional medical advice, diagnosis, or treatment from your pulmonologist.

Get notified when new evidence is published on Sarcoidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.